awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q30539166-0A50844C-606A-4A99-B026-FE5BACA272B9
Q30539166-0A50844C-606A-4A99-B026-FE5BACA272B9
BestRank
Statement
http://www.wikidata.org/entity/statement/Q30539166-0A50844C-606A-4A99-B026-FE5BACA272B9
Evolving therapies for liver fibrosis.
P2860
Q30539166-0A50844C-606A-4A99-B026-FE5BACA272B9
BestRank
Statement
http://www.wikidata.org/entity/statement/Q30539166-0A50844C-606A-4A99-B026-FE5BACA272B9
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
f4afcdffbf26ac03ae2a81f3ed32ab4ba1f9e283
P2860
Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis.